이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

USANA Health Sciences 미래 성장

Future 기준 확인 0/6

USANA Health Sciences 의 수익은 연간 0.3% 감소할 것으로 예상되는 반면, 연간 수익은 1% 로 증가할 것으로 예상됩니다. 1% 연간. EPS는 연간 0.6% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-0.3%

수익 성장률

-0.6%

EPS 성장률

Personal Products 수익 성장	22.9%
매출 성장률	1.0%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	14 Jun 2024

최근 미래 성장 업데이트

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Recent updates

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

May 29

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 03

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Jul 27

USANA Earnings Preview: From China's Challenge To India's Promise

Jul 21

USANA Health Sciences says Brown will transition to CEO in July 2023

Feb 13

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

Feb 02

USANA Health Sciences down 17% after revising 2022 outlook below consensus estimates

Oct 25

Here's What To Make Of USANA Health Sciences' (NYSE:USNA) Decelerating Rates Of Return

Oct 18

Are Investors Undervaluing USANA Health Sciences, Inc. (NYSE:USNA) By 26%?

Jul 22

Returns On Capital At USANA Health Sciences (NYSE:USNA) Have Stalled

Jul 07

Is USANA Health Sciences (NYSE:USNA) Using Too Much Debt?

Jun 14

Is USANA Health Sciences, Inc. (NYSE:USNA) Potentially Undervalued?

May 31

USANA: Soft Quarter, Bottomed Out Stock, 9.8x Ex-Cash P/E, 65% Upside

Apr 28

Capital Investments At USANA Health Sciences (NYSE:USNA) Point To A Promising Future

Mar 05

USANA: 15x P/E, 14% Net Cash, Stock Repurchases

Feb 17

수익 및 매출 성장 예측

NYSE:USNA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	914	61	69	85	2
12/31/2024	884	54	61	78	2
3/30/2024	900	62	60	75	N/A
12/30/2023	921	64	56	71	N/A
9/30/2023	928	60	75	85	N/A
7/1/2023	948	63	79	92	N/A
4/1/2023	974	65	86	97	N/A
12/31/2022	999	69	94	104	N/A
10/1/2022	1,038	77	78	88	N/A
7/2/2022	1,079	89	84	97	N/A
4/2/2022	1,151	108	108	121	N/A
1/1/2022	1,186	117	108	121	N/A
10/2/2021	1,230	136	133	144	N/A
7/3/2021	1,254	139	148	156	N/A
4/3/2021	1,176	129	140	149	N/A
1/2/2021	1,135	125	145	160	N/A
9/26/2020	1,095	116	149	168	N/A
6/27/2020	1,058	110	149	169	N/A
3/28/2020	1,055	103	131	152	N/A
12/28/2019	1,061	101	110	127	N/A
9/28/2019	1,089	102	97	111	N/A
6/29/2019	1,125	109	104	116	N/A
3/30/2019	1,170	121	127	138	N/A
12/29/2018	1,189	126	141	152	N/A
9/29/2018	1,163	88	154	167	N/A
6/30/2018	1,128	81	112	125	N/A
3/31/2018	1,084	70	129	141	N/A
12/30/2017	1,047	63	N/A	124	N/A
9/30/2017	1,027	90	N/A	124	N/A
7/1/2017	1,020	97	N/A	145	N/A
4/1/2017	1,021	99	N/A	125	N/A
12/31/2016	1,006	100	N/A	137	N/A
10/1/2016	986	102	N/A	119	N/A
7/2/2016	965	98	N/A	113	N/A
4/2/2016	940	97	N/A	101	N/A
1/2/2016	918	95	N/A	111	N/A
10/3/2015	914	92	N/A	112	N/A
7/4/2015	872	86	N/A	120	N/A
4/4/2015	827	80	N/A	126	N/A
1/3/2015	790	77	N/A	105	N/A
9/27/2014	749	76	N/A	102	N/A
6/28/2014	731	73	N/A	83	N/A
3/29/2014	731	78	N/A	81	N/A
12/28/2013	718	79	N/A	99	N/A
9/28/2013	700	77	N/A	94	N/A
6/29/2013	692	78	N/A	96	N/A

애널리스트 미래 성장 예측

수입 대 저축률: USNA 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.3% ).

수익 vs 시장: USNA 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -0.3% ).

고성장 수익: USNA 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: USNA 의 수익(연간 1% ) US 시장( 8.7% 보다 느리게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: USNA 의 수익(연간 1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: USNA 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

USANA Health Sciences 미래 성장

Future 기준 확인 0/6

주요 정보

최근 미래 성장 업데이트

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Price target decreased by 17% to US$56.50

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target increased by 8.8% to US$74.00

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

Recent updates

Founder & Chairman Emeritus recently sold US$180k worth of stock

Founder & Chairman Emeritus notifies of intention to sell stock

USANA Health Sciences (NYSE:USNA) Might Be Having Difficulty Using Its Capital Effectively

Chief People Officer recently sold US$132k worth of stock

Now 22% undervalued

Chief Financial Officer recently sold US$233k worth of stock

Insider notifies of intention to sell stock

Insider recently sold US$179k worth of stock

USANA Health Sciences, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

First quarter 2024 earnings: EPS exceeds analyst expectations

Is Now The Time To Look At Buying USANA Health Sciences, Inc. (NYSE:USNA)?

USANA Health Sciences, Inc. to Report Q1, 2024 Results on Apr 30, 2024

USANA Health Sciences, Inc.'s (NYSE:USNA) Prospects Need A Boost To Lift Shares

USANA Health Sciences, Inc., Annual General Meeting, May 06, 2024

New minor risk - Insider selling

Chief Legal Officer recently sold US$232k worth of stock

Price target decreased by 17% to US$56.50

Chief Financial Officer exercised options and sold US$161k worth of stock

New major risk - Revenue and earnings growth

USANA Health Sciences (NYSE:USNA) Could Be Struggling To Allocate Capital

Full year 2023 earnings: EPS exceeds analyst expectations

USANA Health Sciences, Inc. Provides Earnings Guidance for the Fiscal Year 2024

USANA Health Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Is It Too Late To Consider Buying USANA Health Sciences, Inc. (NYSE:USNA)?

Investor sentiment deteriorates as stock falls 15%

Price target increased by 8.8% to US$74.00

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023

USANA: New Digital Tools And Solid Balance Sheet Imply Undervaluation

USANA Health Sciences, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Are Investors Undervaluing USANA Health Sciences, Inc. (NYSE:USNA) By 22%?

Now 21% undervalued after recent price drop

Chief People Officer recently sold US$239k worth of stock

Chief People Officer notifies of intention to sell stock

Here's What's Concerning About USANA Health Sciences' (NYSE:USNA) Returns On Capital

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023

USANA Earnings Preview: From China's Challenge To India's Promise

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

USANA Health Sciences, Inc. to Report Q2, 2023 Results on Jul 25, 2023

Price target increased by 22% to US$64.00

Insufficient new directors

Chief Sales Officer notifies of intention to sell stock

Insider recently sold US$811k worth of stock

Independent Director recently sold US$165k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman of the Board & CEO recently sold US$319k worth of stock

Chairman of the Board & CEO notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Kevin Guest to Transit to the Role of Executive Chairman of USANA Health Sciences, Inc., Effective July 1, 2023

USANA Health Sciences says Brown will transition to CEO in July 2023

Insider recently sold US$116k worth of stock

Chairman of the Board & CEO exercised options and sold US$179k worth of stock

Usana Health Sciences, Inc. Reiterates Consolidated Earnings Guidance for the Fiscal Year 2023

Returns On Capital At USANA Health Sciences (NYSE:USNA) Paint A Concerning Picture

USANA Health Sciences, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

USANA Health Sciences, Inc. (NYSE:USNA) acquired Rise Bar and Oola Global, LLC.

Price target decreased to US$49.00

Consensus EPS estimates fall by 17%

USANA Health Sciences, Inc. Revises Consolidated Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

USANA Health Sciences down 17% after revising 2022 outlook below consensus estimates

Here's What To Make Of USANA Health Sciences' (NYSE:USNA) Decelerating Rates Of Return

USANA Health Sciences, Inc. to Report Q3, 2022 Results on Oct 25, 2022

Now 21% undervalued after recent price drop

Chief People Officer recently sold US$352k worth of stock

Price target decreased to US$55.00